How organoids can improve personalized treatment in patients with gastro-esophageal tumors. (April 2023)

• Record Type: Journal Article
• Authors: Cabeza-Segura, Manuel; Garcia-Micò, Blanca; La Noce, Marcella; Nicoletti, Giovanni Francesco; Conti, Valeria; Filippelli, Amelia; Fleitas, Tania; Cervantes, Andrés; Castillo, Josefa; Papaccio, Federica
• Is Part Of: Current opinion in pharmacology. Volume 69(2023)
• Publication Date: 2023-04
• Subjects: Pharmacology -- Periodicals; Pharmaceutical Preparations -- Periodicals; Drug Therapy -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Periodicals; 615.105
• DOI: 10.1016/j.coph.2023.102348
• Languages: English
• ISSNs: 1471-4892

Abstract

Abstract: Gastro-esophageal tumors constitute a big health problem. Treatment options still mainly rely on chemotherapy, and apart from human epidermal growth factor receptor 2 positive and microsatellite instable/Epstein–Barr Virus disease, there are no molecularly guided options. Therefore, despite the large number of identified molecular alterations, precision medicine is still far from the clinic. In this context, the recently developed technology of patient-derived organoids (PDOs) could offer the chance to accelerate drug development and biomarker discovery. Indeed, PDOs are 3D primary cultures that were shown to reproduce patient's tumor characteristics. Moreover, several reports indicated that PDOs can replicate patient's response to a given drug; therefore, they are one of the most promising tools for functional precision medicine.